Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $205 to $250.
Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $205 to $250.